-
my country has initially formed online and offline integrated medical services, and the country has issued detailed rules to "escort"
Time of Update: 2022-08-15
. In order to standardize the behavior of Internet diagnosis and treatment, the National Health Commission and the State Administration of Traditional Chinese Medicine recently issued the "Internet Diagnosis and Treatment Supervision Rules (Trial)", requiring that the diagnosis and treatment behaviors that occur on the Internet must rely on physical medical institutions to conduct online medical treatment.
-
New perspectives, new ideas!
Time of Update: 2022-08-15
. Topic: Three-dimensional naturalized ecological restoration technology of river corridors Zhang Jing, senior engineer at the Institute of Water Ecology and Environment, China Academy of Water Resources and Hydropower, Deputy Secretary-General of the Eco-Hydraulic Engineering Special Committee of the China Hydraulic Society Open and dynamic, river corridors include floodplains, highland edge transition zones, and river troughs in cross-section.
-
In 2021, the total number of new drug clinical trial registrations in China exceeded 3,000 for the first time, and the research and development of PD-1/PD-L1 is particularly outstanding!
Time of Update: 2022-08-15
The "Report" shows that according to the classification of chemical drugs, biological products and traditional Chinese medicines, from the data analysis of the past three years, the proportion of new drug clinical trials of chemical drugs and biological products is relatively high, with an annual average of 54.
-
All in one article to cover the opportunity of Chinese patent medicine project!
Time of Update: 2022-08-15
2 New improved traditional Chinese medicine: looking for different ways of using drugs to improve the project New improved traditional Chinese medicine drugs, namely Class 2 traditional Chinese medicines, refer to preparations that change the route of administration and dosage form of traditional Chinese medicines already on the market, and have clinical application advantages and characteristics, or increase functions and indications; they are further subdivided into 2.
-
The clinical trial of Zhongsheng Pharmaceutical's oral new crown drug RAY1216 was accepted today's daily limit
Time of Update: 2022-08-15
On the evening of May 11, Zhongsheng Pharmaceutical issued an announcement stating that the clinical trial registration application for the innovative drug RAY1216 tablets of oral anti-new coronavirus 3CL protease inhibitor, Zhongsheng Ruichuang, a holding subsidiary, was accepted by the National Medical Products Administration (NMPA).
-
CDE: "Guidelines for Blinding of Drug Clinical Trials" Released for Comments
Time of Update: 2022-08-15
Scan the QR code to view the original text Source: National Bureau Review Center Editor: wangxinlai2004 On July 25, 2022, the Evaluation Center of the State Administration issued the "Guiding Principles for Blinding of Drug Clinical Trials (Draft for Comment)", and the time limit for soliciting comments is 1 month from the date of release .
-
Innovative drugs and medical devices are still favored by capital, with over 300 investment and financing events in the first half of the year
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] In the first half of 2022, affected by factors such as the adjustment of the approval policy for innovative drugs and the uncertainty of the expected value realization of biopharmaceutical companies by the capital market, the investment and financing trend in the medical and health sector has slowed down as a whole .
-
Eli Lilly, Novo Nordisk, Sanofi accused of conspiring to push up insulin prices
Time of Update: 2022-08-15
CompileDravenThe state of Arkansas has taken Eli Lilly, Novo Nordisk, Sanofi and three major Pharmacy Benefits Managers (PBMs) to court, accusing them of conspiring to raise the price of insulin and other diabetes-related drugs .
-
In order to improve the efficiency of research and development, there is constant news of cooperation between pharmaceutical companies and technology companies!
Time of Update: 2022-08-15
Recently, Yunnan Baiyao announced that it has signed a comprehensive cooperation agreement with Huawei to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, including large and small molecule design, related diseases, database development, etc.
-
The world's first FcRn antagonist is about to be launched in China, bringing new hope to 200,000 patients
Time of Update: 2022-08-15
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
Retrieved Oct 23, 2017, from https:// -Soliris%C2%AE-Eculizumab-for-the-Treatment-of-Patients-with-Generalized-Myasthenia-Gravis-gMG; 4.
-
Another new drug withdrew its drug registration application!
Time of Update: 2022-08-15
Buchang Pharmaceutical announced on the evening of May 9 that due to the need to further improve the application materials for fasudil hydrochloride injection, after careful research and decision, Tonghua Guhong applied to the State Food and Drug Administration to withdraw the drug registration of fasudil hydrochloride injection apply .
-
The State Food and Drug Administration cancels the medical device registration certificate of Tianzhihang Medical and other enterprises
Time of Update: 2022-08-15
, On May 10, in accordance with the "Regulations on the Supervision and Administration of Medical Devices", according to the application of enterprises, the State Food and Drug Administration cancelled the registration certificates of medical devices for 6 products below 3 companies including Shenzhen Boka Biotechnology Co.
-
The listing application of Chia Tai Tianqing TQ-B3101 capsules was accepted
Time of Update: 2022-08-15
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
. TQ-B3101 is a novel small molecule receptor tyrosine kinase inhibitor targeting ALK/ROS1/MET .
Preclinical studies have shown that the drug has good antitumor activity and duration of efficacy .
-
CPhI & P-MEC China 2022 postponed to December
Time of Update: 2022-08-15
After fully listening to the opinions and feedback of relevant parties, and actively communicating with the exhibition hall and relevant departments, the exhibition organizer co-organized a comprehensive research decision: the 21st World Pharmaceutical Raw Materials China Exhibition and the 16th World Pharmaceutical Machinery and Packaging Equipment The CPhI & P-MEC China 2022 has been postponed to December 20-22, 2022, and the venue remains unchanged at the Shanghai New International Expo Center .
-
In August, a large number of pharmaceutical companies announced that their products passed the consistency evaluation. Northeast Pharmaceuticals, Lianhuan Pharmaceuticals, etc.
Time of Update: 2022-08-15
Bihuan Pharmaceutical: Drotaverine Hydrochloride Injection was over-reviewed and won the first one On August 5, Bihuan Pharmaceutical announced that the company's Drotaverine Hydrochloride Injection has recently passed the quality and efficacy consistency evaluation of generic drugs .
-
In order to accelerate innovation, domestic pharmaceutical companies are "grouping together"
Time of Update: 2022-08-15
Recently, China Resources Double Crane issued an announcement to sign the "Strategic Cooperation Agreement" and "Azvudine Tablet Entrusted Processing and Production Framework Agreement" with Real Bio. Expand cooperation in the field .
-
Competing for the $20.7 billion antibody-conjugated drug market, many pharmaceutical companies have "going overseas" one after another
Time of Update: 2022-08-15
2 antibody-drug conjugate SYSA1801 in large-scale Development and commercialization rights outside of China For example, on July 28, CSPC announced that its subsidiary CSPC Jushi Biology signed an exclusive licensing agreement with Elevation Oncology, and Elevation Company will obtain CSPC Jushi Bio's innovative anti-Claudin18.
-
The research and development hotspots of innovative therapeutics and pharmaceutical companies, these areas have become the focus of attention
Time of Update: 2022-08-15
For example, on the 17th, Travere Therapeutics announced that the US FDA has granted the company priority review status for the new drug application submitted by the company for the investigational therapy sparsentan for the treatment of IgA nephropathy .
-
The county-level drug market will expand again, and pharmaceutical companies will usher in a new round of development opportunities
Time of Update: 2022-08-15
For example, in November last year, the National Health and Medical Commission issued the "Thousand-County Project" County Hospital Comprehensive Capacity Improvement Work Plan (2021-2025), which determined that by 2025 at least 1,000 county-level medical institutions across the country will reach Level 3.
-
The treatment of non-small cell lung cancer exceeds US$400 million to help develop differentiated EGFR inhibitors
Time of Update: 2022-08-15
Image source: Cullinan Oncology's official websiteUnder the terms of the agreement, Taiho will acquire Cullinan Pearl, which owns the global development rights for CLN-081/TAS6417 outside of Japan, and will pay Cullinan Oncology an upfront payment of $275 million, as well as regulatory milestones related to EGFR exon 20 insertion mutant NSCLC.
